Adenocarcinoma of Lung
/ genetics
Alleles
Cell Line, Tumor
Cohort Studies
ErbB Receptors
/ antagonists & inhibitors
Gefitinib
/ pharmacology
Gene Expression Regulation, Neoplastic
Humans
MicroRNAs
/ genetics
Neoplasm Staging
Polymorphism, Single Nucleotide
Protein Kinase Inhibitors
/ pharmacology
Transcription, Genetic
/ drug effects
EGFR-TKIs
gene expression
genetic polymorphism
lung adenocarcinoma
miR-1262
Journal
DNA and cell biology
ISSN: 1557-7430
Titre abrégé: DNA Cell Biol
Pays: United States
ID NLM: 9004522
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
pubmed:
29
4
2020
medline:
21
7
2020
entrez:
29
4
2020
Statut:
ppublish
Résumé
Advanced nonsmall-cell lung cancer (NSCLC) patients with mutated epidermal growth factor receptor (EGFR) can remarkably benefit from target therapy of EGFR-tyrosine kinase inhibitors (TKIs). However, increasing drug sensitivity and improving outcomes of NSCLC patients to EGFR-TKI therapy remains a challenge. Several studies have shown a link between microRNAs and drug resistance in cancer. In this study, we hypothesized that the rs12740674 single nucleotide polymorphism in the enhancer of
Identifiants
pubmed: 32343915
doi: 10.1089/dna.2020.5457
doi:
Substances chimiques
MIRN1262 microRNA, human
0
MicroRNAs
0
Protein Kinase Inhibitors
0
ErbB Receptors
EC 2.7.10.1
Gefitinib
S65743JHBS
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM